Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Cas-SF01, an engineered Cas12i nuclease is an efficient genome editing tool in mammalian cells and plants

ABSTRACT: Cas-SF01, an engineered Cas12i nuclease is an efficient genome editing tool in mammalian cells and plants

PROVIDER: PRJNA992370 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR25182338_1.fastq.gz	Fastqsanger.gz
	SRR25182338_2.fastq.gz	Fastqsanger.gz
	SRR25182339_1.fastq.gz	Fastqsanger.gz
	SRR25182339_2.fastq.gz	Fastqsanger.gz
	SRR25182340_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

Cas-SF01, an engineered Cas12i nuclease is an efficient genome editing tool in mammalian cells and plants

Project description:The type V-I CRISPR-Cas system is becoming increasingly attractive for its potential utility in gene editing. However, natural nucleases often exhibit low efficiency, limiting their application. Here, we utilized structure-guided rational design and combinatorial protein engineering to optimize an uncharacterized Cas12i nuclease, Cas12i3. Accordingly, we developed Cas-SF01, a Cas12i3 variant that exhibits significantly improved gene-editing activity in mammalian cells and plants. Cas-SF01 displays comparable or superior editing performance compared to SpCas9 or recently engineered Cas12 nucleases. Further analysis of PAM recognition showed that Cas-SF01 has an expanded PAM range and effectively recognizes NTTN and noncanonical NATN and TTVN PAMs. Additionally, we identified an amino acid substitution, D876R, that markedly reduced the off-target effect while maintaining high on-target activity, leading to the development of Cas-SF01HiFi (high-fidelity Cas-SF01). Finally, we demonstrated that Cas-SF01 has robust gene-editing activity in both the monocot plant rice and dicot plant pepper. Our results suggest that Cas-SF01 can serve as a robust gene-editing platform with high efficiency and specificity for future genome editing applications across different organisms.

2023-11-05 | GSE236755 | GEO

Deep sequencing data from PFS screen of SuCas12a2 CRISPR-Cas nuclease

Project description:In this work we analyzed PFS sequence recognized by SuCas12a2 Type V CRISPR-Cas nuclease

2023-01-11 | GSE178530 | GEO

Engineered miniature CRISPR-Cas system for mammalian genome regulation and editing

Project description:Compact and versatile CRISPR-Cas systems will enable genome engineering applications through high-efficiency delivery in a wide variety of contexts. Here we create an efficient miniature Cas system (CasMINI) engineered from the type V-F Cas12f (Cas14) system by guide RNA and protein engineering, which is less than half the size of currently used CRISPR systems (Cas9 or Cas12a). We demonstrate that CasMINI can drive high levels of gene activation (up to thousands-fold increases), while the natural Cas12f system fails to function in mammalian cells. We show that the CasMINI system has comparable activities to Cas12a for gene activation, is highly specific, and allows for robust base editing and gene editing. We expect that CasMINI can be broadly useful for cell engineering and gene therapy applications ex vivo and in vivo.

2021-09-10 | GSE180773 | GEO

Engineered miniature CRISPR-Cas system for mammalian genome regulation and editing

Project description:Engineered miniature CRISPR-Cas system for mammalian genome regulation and editing

| PRJNA749464 | ENA

Scaffold RNA engineering in type V CRISPR-Cas systems: a potent way to enhance gene expression in the yeast Saccharomyces cerevisiae.

Project description:New, orthogonal transcription factors in eukaryotic cells have been realized by engineering nuclease-deficient CRISPR-associated proteins and/or their guide RNAs. In this work, we present a new kind of orthogonal activators, in Saccharomyces cerevisiae, made by turning type V CRISPR RNA into a scaffold RNA (ScRNA) able to recruit a variable number of VP64 activation domains. The activator arises from the complex between the synthetic ScRNA and DNase-deficient type V Cas proteins: dCas12e and denAsCas12a. The transcription activation achieved via the newly engineered dCas:ScRNA system is up to 4.7-fold higher than that obtained with the direct fusion of VP64 to Cas proteins. The new transcription factors have been proven to be functional in circuits such as Boolean gates, converters, multiplex-gene and metabolic-pathway activation. Our results extend the CRISPR-Cas-based technology with a new effective tool that only demands RNA engineering and improves the current design of transcription factors based on type V Cas proteins.

2023-12-05 | GSE249355 | GEO

Deep sequencing data from PFS screen of SuCas12a2 CRISPR-Cas nuclease

Project description:Deep sequencing data from PFS screen of SuCas12a2 CRISPR-Cas nuclease

| PRJNA739561 | ENA

CRISPR-Cas protein Cas3 controls virulence in the oral pathogen Porphyromonas gingivalis.

Project description:Our results show that compared to wild type, a deletion mutant of the cas3 gene, an essential nuclease part of the class 1 type I CRISPR-Cas system, increases the virulence of P gingivalis.

2020-09-16 | GSE154569 | GEO

Efficient engineering of human and mouse primary cells using peptide-assisted genome editing

Project description:Simple and efficient delivery of CRISPR genome editing systems in primary cells remains a major challenge. Here, we describe an engineered Peptide-Assisted Genome Editing (PAGE) CRISPR-Cas system for rapid and robust editing of primary cells. PAGE couples a cell-penetrating Cas protein with a cell-penetrating endosomal escape peptide in a 30-minute incubation that yields up to ~98% editing efficiency in primary human and mouse T cells. PAGE provides a broadly generalizable platform for next generation genome engineering in primary cells. CITATION INFORMATION: Zhang Zhen, Baxter Amy E, Ren Diqiu, Qin Kunhua, Chen Zeyu, Collins Sierra M., Huang Hua, Komar Chad A., Bailer Peter F., Parker Jared B., Blobel Gerd A., Kohli Rahul M., Wherry E. John*, Berger Shelley,*, and Shi Junwei*. Peptide-assisted genome editing permits efficient CRISPR engineering of primary T cells.

2023-03-20 | GSE223805 | GEO

An Improved SNAP-ADAR Tool Enables Efficient RNA Base Editing to Interfere with Post-translational Protein Modification

Project description:RNA base editing applies endogenous or engineered adenosine deaminases to introduce adenosine-to-inosine changes into a target RNA in a highly programmable manner. Recently, notable success was achieved for the repair of disease-causing guanosine-to-adenosine mutations by means of RNA base editing. Here, we propose that RNA base editing could be broadly applied to perturb protein function by removal of regulatory sites of post-translational modification (PTM), like phosphorylation and/or acetylation sites. We demonstrate the feasibility of PTM interference (PTMi) on more than 70 PTM sites in various signaling proteins and identify key determinants for high editing efficiency and potent down-stream effects. Specifically, we demonstrate both negative and positive regulation of the JAK/STAT pathway by PTMi. To identify potent regulatory sites for PTMi, we applied an improved version of the SNAP-ADAR tool, which achieved high editing efficiency over a broad codon scope with tight control of bystander editing. The transient nature of RNA base editing enables the fast, dose-dependent (thus partial) and reversible manipulation of PTM sites, which is a key advantage over DNA editing approaches, where genetic compensation or lethality can conceal a phenotype. In summary, PTM interference might become a valuable field of application of RNA base editing in basic biology and medicine.

2024-04-19 | GSE264114 | GEO

Defining genome-wide CRISPR-Cas genome-editing nuclease activity with GUIDE-seq.

Project description:Genome-wide unbiased identification of double-stranded breaks enabled by sequencing (GUIDE-seq) is a sensitive, unbiased, genome-wide method for defining the activity of genome-editing nucleases in living cells. GUIDE-seq is based on the principle of efficient integration of an end-protected double-stranded oligodeoxynucleotide tag into sites of nuclease-induced DNA double-stranded breaks, followed by amplification of tag-containing genomic DNA molecules and high-throughput sequencing. Here we describe a detailed GUIDE-seq protocol including cell transfection, library preparation, sequencing and bioinformatic analysis. The entire protocol including cell culture can be completed in 9 d. Once tag-integrated genomic DNA is isolated, library preparation, sequencing and analysis can be performed in 3 d. The result is a genome-wide catalog of off-target sites ranked by nuclease activity as measured by GUIDE-seq read counts. GUIDE-seq is one of the most sensitive cell-based methods for defining genome-wide off-target activity and has been broadly adopted for research and therapeutic use.

| S-EPMC9331158 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data